Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below 200 Day Moving Average – Time to Sell?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.80 and traded as low as $0.68. Karyopharm Therapeutics shares last traded at $0.70, with a volume of 433,181 shares trading hands.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Piper Sandler upped their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Trading Up 1.7 %

The stock’s 50-day moving average is $0.73 and its 200-day moving average is $0.80.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01. The business had revenue of $38.78 million for the quarter, compared to analysts’ expectations of $37.86 million. During the same quarter last year, the company posted ($0.30) earnings per share. Analysts expect that Karyopharm Therapeutics Inc. will post -0.96 earnings per share for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several large investors have recently added to or reduced their stakes in KPTI. GSA Capital Partners LLP increased its holdings in shares of Karyopharm Therapeutics by 80.6% during the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after purchasing an additional 792,283 shares during the period. AQR Capital Management LLC increased its holdings in shares of Karyopharm Therapeutics by 494.5% during the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after purchasing an additional 622,194 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Karyopharm Therapeutics during the second quarter valued at $494,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Karyopharm Therapeutics during the second quarter valued at $143,000. Finally, FMR LLC increased its holdings in shares of Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after purchasing an additional 76,510 shares during the period. 66.44% of the stock is currently owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).